CRISPR/Cas technologies for cancer drug discovery and treatment
Trends in Pharmacological Sciences · 2025
DOI: 10.1016/j.tips.2025.02.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2025. Verfasst von Kevin C Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, M5S 1A8, Canada. Hauptthemen laut MEDLINE: Neoplasms, CRISPR-Cas Systems, Drug Discovery, Antineoplastic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Cancer Research Society.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, M5S 1A8, Canada. Electronic address: basil.hubbard@utoronto.ca.
Förderung
- Canadian Institutes of Health Research
- Cancer Research Society
Zitieren
APA
Wang, K. C., Zheng, T., & Hubbard, B. P. (2025). CRISPR/Cas technologies for cancer drug discovery and treatment. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2025.02.009
Vancouver
Wang KC, Zheng T, Hubbard BP. CRISPR/Cas technologies for cancer drug discovery and treatment. Trends in Pharmacological Sciences. 2025. doi:10.1016/j.tips.2025.02.009
BibTeX
@article{Wang2025,
author = {Wang, Kevin C and Zheng, Tiffany and Hubbard, Basil P},
title = {CRISPR/Cas technologies for cancer drug discovery and treatment},
journal = {Trends in Pharmacological Sciences},
year = {2025},
doi = {10.1016/j.tips.2025.02.009}
}
EUVIMED